← Back to Screener
SCYNEXIS, Inc. (SCYX)
Price$1.07
Favorite Metrics
Price vs S&P 500 (26W)24.87%
Price vs S&P 500 (4W)14.08%
Market Capitalization$47.85M
All Metrics
Book Value / Share (Quarterly)$1.13
P/TBV (Annual)1.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)59.36%
Cash Flow / Share (Quarterly)$-0.12
Price vs S&P 500 (YTD)65.27%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-41.79%
EPS (TTM)$-0.18
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-0.18
Revenue Growth (5Y)99.01%
EPS (Annual)$-0.17
ROI (Annual)-17.44%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-409.20%
Cash / Share (Quarterly)$0.92
Revenue Growth QoQ (YoY)1808.50%
ROA (Last FY)-14.58%
Revenue Growth TTM (YoY)449.95%
EBITD / Share (TTM)$-0.21
ROE (5Y Avg)-401.32%
Operating Margin (TTM)-77.93%
Cash Flow / Share (Annual)$-0.12
P/B Ratio0.97x
P/B Ratio (Quarterly)0.54x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.29x
Net Interest Coverage (TTM)31.96x
ROA (TTM)-14.43%
EV / EBITDA (TTM)0.26x
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)7.04x
Quick Ratio (Quarterly)7.00x
3-Month Avg Trading Volume0.54M
52-Week Price Return18.32%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$1.96
P/S Ratio (Annual)2.32x
Asset Turnover (Annual)0.35x
52-Week High$1.31
Operating Margin (5Y Avg)-636.97%
EPS Excl Extra (Annual)$-0.17
Tangible BV CAGR (5Y)-33.31%
26-Week Price Return31.76%
Quick Ratio (Annual)7.00x
13-Week Price Return66.64%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.04x
Enterprise Value$26.594
Revenue / Share Growth (5Y)29.25%
Asset Turnover (TTM)0.35x
Book Value / Share Growth (5Y)-0.32%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.92x
Pretax Margin (Annual)-41.79%
Cash / Share (Annual)$0.92
3-Month Return Std Dev75.76%
Gross Margin (5Y Avg)75.47%
Net Income / Employee (TTM)$-0
ROE (Last FY)-17.44%
Net Interest Coverage (Annual)8.40x
EPS Basic Excl Extra (Annual)$-0.17
P/FCF (TTM)2.60x
Receivables Turnover (TTM)133.52x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.18
Receivables Turnover (Annual)133.47x
ROI (TTM)-19.05%
P/S Ratio (TTM)2.32x
Pretax Margin (5Y Avg)-431.52%
Revenue / Share (Annual)$0.41
Tangible BV / Share (Annual)$1.96
Price vs S&P 500 (52W)-16.31%
Year-to-Date Return69.20%
5-Day Price Return4.90%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-16.97%
Net Profit Margin (Annual)-41.79%
Month-to-Date Return16.70%
EBITD / Share (Annual)$-0.21
Operating Margin (Annual)-78.03%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-27.82%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.18
P/TBV (Quarterly)1.14x
P/B Ratio (Annual)0.54x
Inventory Turnover (TTM)34.63x
Pretax Margin (TTM)-41.79%
Book Value / Share (Annual)$1.13
Price vs S&P 500 (13W)64.26%
Beta1.27x
P/FCF (Annual)0.80x
Revenue / Share (TTM)$0.41
ROE (TTM)-19.05%
52-Week Low$0.56
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SCYXSCYNEXIS, Inc. | 2.32x | 449.95% | 100.00% | — | $1.07 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
SCYNEXIS develops novel antifungal therapies to treat serious fungal infections with significant unmet medical needs. The company's lead candidate, ibrexafungerp, is an oral and intravenous glucan synthase inhibitor demonstrating broad-spectrum activity against drug-resistant Candida and Aspergillus species. The medication's differentiated mechanism of action offers potential advantages over existing antifungal treatments for invasive fungal infections.